# Study of Roxadustat Conversion in Participants Receiving Stable ESA or as Initial Anemia Treatment in Hemodialysis Participants

> **NCT04484857** · PHASE3 · COMPLETED · sponsor: **Kyntra Bio** · enrollment: 283 (actual)

## Conditions studied

- Anemia Associated With End Stage Renal Disease

## Interventions

- **DRUG:** Roxadustat

## Key facts

- **NCT ID:** NCT04484857
- **Lead sponsor:** Kyntra Bio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-22
- **Primary completion:** 2021-07-09
- **Final completion:** 2021-09-17
- **Target enrollment:** 283 (ACTUAL)
- **Last updated:** 2022-07-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04484857

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04484857, "Study of Roxadustat Conversion in Participants Receiving Stable ESA or as Initial Anemia Treatment in Hemodialysis Participants". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04484857. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*